Monograph

N03AX14 - Levetiracetam

Propably not porphyrinogenic

Rationale

Non-oxidative metabolism. No data pointing to CYP-interaction.

Chemical description

Pyrrolidone derivative used in additional treatment of partial epileptic attacks.The major metabolic pathway (24 % of the dose) is an enzymatic hydrolysis of the acetamide group. Does not interact with CYPs. See: Paul and Meencke. Levitiracetam in focal epilepsia and hepatic porphyria: a case report. Epilepsia 2004; 45: 559-60 ( No exacerbation noed)

IPNet drug reports

Uneventful use reported in 6 patients with acute porphyria.

Similar drugs

Explore alternative drugs in similar therapeutic classes N03A / N03AX or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames